Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan.
Matsumoto R, Abe T, Ishizaki J, Kikuchi H, Harabayashi T, Minami K, Sazawa A, Mochizuki T, Akino T, Murakumo M, Osawa T, Maruyama S, Murai S, Shinohara N. Matsumoto R, et al. Among authors: murakumo m. Jpn J Clin Oncol. 2018 Aug 1;48(8):771-776. doi: 10.1093/jjco/hyy094. Jpn J Clin Oncol. 2018. PMID: 29939285 Free PMC article.
Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
Abe T, Ishizaki J, Kikuchi H, Minami K, Matsumoto R, Harabayashi T, Sazawa A, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Maruyama S, Murai S, Shinohara N. Abe T, et al. Among authors: murakumo m. Urol Oncol. 2017 Feb;35(2):38.e1-38.e8. doi: 10.1016/j.urolonc.2016.08.016. Epub 2016 Sep 29. Urol Oncol. 2017. PMID: 27693091 Free article.
Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma.
Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, Miyata H, Matsumoto R, Osawa T, Maruyama S, Ishizaki J, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Murai S, Shinohara N. Abe T, et al. Among authors: murakumo m. Jpn J Clin Oncol. 2019 Oct 1;49(10):965-971. doi: 10.1093/jjco/hyz084. Jpn J Clin Oncol. 2019. PMID: 31187865 Free PMC article.
Erratum to: Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma.
Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, Miyata H, Matsumoto R, Osawa T, Maruyama S, IshizakiIshizaki J, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Murai S, Shinohara N. Abe T, et al. Among authors: murakumo m. Jpn J Clin Oncol. 2020 Jun 10;50(6):726. doi: 10.1093/jjco/hyz196. Jpn J Clin Oncol. 2020. PMID: 32382760 Free PMC article. No abstract available.
Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
Shinohara N, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, Mitsuhashi K, Demura T, Nagamori S, Matsuyama H, Naito K, Nonomura K. Shinohara N, et al. Among authors: murakumo m. Cancer Chemother Pharmacol. 2006 Sep;58(3):402-7. doi: 10.1007/s00280-005-0175-4. Epub 2006 Jan 17. Cancer Chemother Pharmacol. 2006. PMID: 16416335 Clinical Trial.
24 results